Compugen (CGEN) Corporate presentation summary

Vision and platform

• Aims to transform patient lives by developing first-in-class therapeutics using an AI/ML-powered computational target discovery platform.

• Proprietary Unigen™ platform enables rapid hypothesis generation, target validation, and identification of novel biomarkers and drug candidates.

Clinical pipeline and partnerships

• Focuses on novel immuno-oncology antibodies, including COM701 (anti-PVRIG) and COM902 (anti-TIGIT), both with Fc-reduced functionality.

• Rilvegostomig, a PD-1/TIGIT bispecific antibody (TIGIT component from COM902), is in Phase 3 with AstraZeneca, targeting >$5B peak year revenue.

• GS-0321 (anti-IL-18BP) licensed to Gilead, with up to $848M deal value and tiered royalties; Compugen leads preclinical and Phase 1 development.

• Cash balance of $145.6M as of December 31, 2025, with expected runway into 2029.

COM701: Clinical data and rationale

• COM701 shows clinical benefit in platinum-resistant ovarian cancer, including PD-L1 negative and heavily pretreated patients.

• Durable responses observed as monotherapy and in combinations, with ORR up to 20% and DCR up to 46%.

• Safety profile is favorable, with most adverse events grade 1/2 and low discontinuation rates.

• Strong rationale for advancing to platinum-sensitive ovarian cancer, a less competitive and less immune-compromised setting.

• MAIA-ovarian adaptive trial initiated in Q2 2025, with interim analysis projected for Q1 2027.